Oryn Therapeutics (United States)

Recent papers from Oryn Therapeutics (United States)

1. Distributed Settlement, Multiparty Authority, and Economic-State Continuity2026
2. Obligation Finality, Custody-State Integrity, and Consequential Financial Closure2026
3. Partial Settlement, Compensating Execution, and Economic-State Continuity2026
4. Obligation Finality, Custody-State Integrity, and Consequential Financial Closure2026
5. Morning Star: Formal Specification of Constitutional Admission, Authority, Evidence, Scope, Invariant Preservation, and Executable Transition2026
6. Preclinical Pharmacokinetics and Safety of Intravenous RTD-1Antimicrobial Agents and Chemotherapy · 2022
7. A host-directed macrocyclic peptide therapeutic for MDR gram negative bacterial infectionsScientific Reports · 2021
8. Host Defense Peptides as Templates for Antifungal Drug DevelopmentJournal of Fungi · 2020
9. RTD-1 therapeutically normalizes synovial gene signatures in rat autoimmune arthritis and suppresses proinflammatory mediators in RA synovial fibroblastsPhysiological Genomics · 2019
10. Rhesus Theta Defensin 1 Promotes Long Term Survival in Systemic Candidiasis by Host Directed MechanismsScientific Reports · 2019
11. Suppression and resolution of autoimmune arthritis by rhesus θ-defensin-1, an immunomodulatory macrocyclic peptidePLoS ONE · 2017
12. Between‐Batch Pharmacokinetic Variability Inflates Type I Error Rate in Conventional Bioequivalence Trials: A Randomized Advair Diskus Clinical TrialClinical Pharmacology & Therapeutics · 2016
13. Batch‐to‐batch pharmacokinetic variability confounds current bioequivalence regulations: A dry powder inhaler randomized clinical trialClinical Pharmacology & Therapeutics · 2016
14. Evaluation of a Scenario in Which Estimates of Bioequivalence Are Biased and a Proposed Solution: t last (Common)The Journal of Clinical Pharmacology · 2015